期刊文献+

HE4和SCC联合检测在宫颈癌诊断中的应用价值 被引量:6

下载PDF
导出
摘要 目的:探讨人附睾蛋白(HE4)和鳞状细胞癌抗原(SCC)联合检测在宫颈癌诊断中的应用价值。方法:分别用电化学发光免疫分析法和微粒子酶免疫分析法检测宫颈癌患者(n=66)、健康体检者(n=152)的血清HE4和SCC的浓度。结果:宫颈癌患者的血清HE4和SCC浓度明显高于健康体检者,差异具有统计学意义(P<0.01);单独检测HE4对宫颈癌诊断的敏感性为40.90%,特异性为78.94%;单独检测SCC的敏感性为71.21%,特异性为88.16%;HE4和SCC联合检测的敏感性为87.88%,特异性为90.78%。结论:HE4与SCC联合检测极大地提高了对宫颈癌诊断的灵敏度。
出处 《包头医学院学报》 CAS 2013年第4期53-54,共2页 Journal of Baotou Medical College
  • 相关文献

参考文献4

二级参考文献26

  • 1甘玉杰,符丽华,徐强(编校).液基细胞学在宫颈病变筛查的分析[J].中国妇幼保健,2007,22(16):2195-2196. 被引量:15
  • 2Drapkin R,Von Horsten HH,Lin Y,et al.Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas[J].Cancer Res,2005,65(6):2162-2169. 被引量:1
  • 3Galgano MT,Hampton GM,Frierson HF Jr.Comprehensive analysis of HE4 expression in normal and malignant human tissues[J].Mod Pathol,2006,19(6):847-853. 被引量:1
  • 4Hellstr(o)m I,Raycraft J,Hayden-Ledbetter M,et al.The HE4 (WFDC2)protein is a biomarker for ovarian carcinoma[J].Cancer Res,2003,63 (13):3695-3700. 被引量:1
  • 5Moore RG,Brown AK,Miller MC,et al.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J].Gynecol Oncol,2008,108(2):402-408. 被引量:1
  • 6Moore RG,McMeekin DS,Brown AK,et al.A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[J].Gynecol Oncol,2009,112(1):40-46. 被引量:1
  • 7Havrilesky LJ,Whitehead CM,Rubatt JM,et al.Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence[J].Gynecol Oncol,2008,110 (3):374-382. 被引量:1
  • 8Kbel M,Kalloger SE,Boyd N,et al.Ovarian carcinoma subtypes are different diseases:implications for biomarker studies[J].Plo S Med,2008,5(12):e232. 被引量:1
  • 9Moore RG,Brown AK,Miller MC,et al.Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus[J].Gynecol Oncol,2008,110(2):196-201. 被引量:1
  • 10Bignotti E,Ragnoli M,Zanotti L,et al.Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients[J].BrJCancer,2011,104(9):1418-1425. 被引量:1

共引文献20

同被引文献59

  • 1刘晓玲,车少敏,王文,姜缨,郑伟.血清SCC与宫颈癌生物学行为的相关性及临床意义[J].西安交通大学学报(医学版),2004,25(6):576-577. 被引量:16
  • 2章文华.宫颈病变的诊治要点[M].北京:人民卫生出版社,2006:78-79. 被引量:1
  • 3Simmons AR, Baggerly K, Bast RC Jr. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas [J]. Oncology (Williston Park) ,2013,27(6) :548-556. 被引量:1
  • 4唐华.联合检测血清CA125、SCCA、HE4、CEA对宫颈癌诊疗价值的研究[J].医药前沿,2014,4(20):9-10. 被引量:1
  • 5Stiekema A, Boldingh QJ, Korse CM. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin[J]. Gynecol Oncol, 2015, 136 (3): 562-566. 被引量:1
  • 6Abdel-Azeez HA, Labib HA, Sharaf SM, et al. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev, 2010, 11(1): 111-116. 被引量:1
  • 7Kim K, Zang R, Choi SC, et al. Current status of gynecological cancer in China [ J ]. Gynecol Onco, 2009,20 ( 2 ) :72. DOI: 10. 3802/jgo. 2009.20.2.72. 被引量:1
  • 8Cruiekshank ME. The role of human papillomavirus in risk man- agement [ J ]. Gynaecol Practice, 2003,3 : 2292-2331. DOI: 10. 1016/S1471-7697 (03) 00057-1. 被引量:1
  • 9Abraham J, Stenger M. Cobas HPV test for first-line screening for cervical cancer [ J ]. J Community Support 0ncol,2014,12 ( 5 ) : 156-157. 被引量:1
  • 10Park IU, Wojtal N, Silvrberg M J, et al. Cytology and human papil- lomavirus co-test results preceding incident high-grade cervical intraepithelial neoplasia[J]. Plos One, 2015,10 ( 3 ) : e0118938. DOI : 10. 1371/joumal. pone. 0118938. 被引量:1

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部